Is Oklo Stock a Buy Now?

Oklo acquired radioisotope company Atomic Alchemy in a $25 million all-stock deal and struck a 1.2 GW power agreement with Meta to support regional data centers, its first major commercial partnership. The company is still pre-revenue, with operating expenses rising to $139M in 2025 from $52M the prior year and shares trading around $52 (peak $193); an NRC commercial operating license—critical for revenue—remains pending and is a make-or-break catalyst. Successful licensing and project execution would materially re-rate the stock; failure to secure the NRC license would likely be catastrophic.

Analysis

Oklo’s moves create two separate optionalities: near-term cash-flow optionality from selling high-margin, short-cycle radioisotopes and long-duration asset optionality from supplying baseload power to large, predictable customers. If isotope operations can capture even $50–150m annual EBITDA within 24 months, that can fund a material portion of reactor capex and compress the company’s financing runway by 12–24 months versus a pure-power path.

Hyperscaler-style offtake structures (prepayments, take-or-pay contracts, project equity contributions) materially change the funding math: a 20–30% upfront prepayment on a multi-hundred-MW deployment can shave hundreds of millions of external capital needs and convert a merchant-risk project into a near-contract, investment-grade cashflow profile for lenders. That reduces required equity dilution and raises takeover/strategic-acquirer optionality from utilities or sovereign funds over a 2–5 year window.

Primary tail risks remain binary regulatory outcomes and supply-chain execution: long-lead forgings, TRISO/HALEU supply concentration, and commissioning staffing can add 12–36 months and 20–40% cost overruns to base schedules. Market reaction to a regulatory setback is likely non-linear — expect >50% downside for equity if licensing slips beyond 12 months, but a favorable license plus a multi-hyperscaler pipeline could support >3x equity upside within 18–36 months.

The right framing for investors is asymmetric optionality with tight position sizing. Treat exposure as event-driven venture capital: buy convexity via limited-loss instruments ahead of the next regulatory/capex funding milestones, and use pair-hedges tied to hyperscaler capex cycles to neutralize broader tech beta over 6–18 months.

Key Decisions for Investors

• Long convexity: Allocate 0.5–1.0% NAV to an OKLO Jan-2028 call spread (buy LEAP call, sell further OTM LEAP) to cap downside while retaining 3–5x upside if licensing + commercial offtake progress within 12–24 months. Target payoff if approval + two contracted projects announced; max loss = premium paid.
• Event hedge: Simultaneously buy 6–12 month puts on OKLO equal to ~25% notional of the call-spread size to protect against a binary regulatory denial that could >50% compress the stock in days. Cost should be <0.25% NAV for the protection layer.
• Relative-value pair: Short sector/construction-exposed nuclear supplier ETF or single large-cap supplier (size 1–2x relative) while holding the OKLO call spread to isolate positive regulatory/contract news and limit exposure to supply-chain, inflation-driven cost blowouts. Close if project finance syndication is announced.
• Hyperscaler play: Overweight a large-scale tech customer (ticker: META) by 1–2% NAV via equity or 12–18 month call spread to capture upside from improved long-term power cost visibility and potential margin tailwinds; trim on +20–30% move or if company announces materially higher renewables/nuclear capex commitments.